<DOC>
	<DOCNO>NCT01657669</DOCNO>
	<brief_summary>This open label study evaluate 2.0 mg intravitreal aflibercept injection administer subject active choroidal neovascularization due Age Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Short-term Clinical Effects Intravitreal Aflibercept Injection 2.0mg Predictor Long-term Results</brief_title>
	<detailed_description>Twenty ( 20 ) consent participant meet inclusion criterion enrol follow 48 week . All subject receive 2.0 mg intravitreal aflibercept injection three initial monthly dos , mandatory dos Weeks 16 , 24 , 32 , 40 . Dosing monthly interval allow needed opinion investigator base presence fluid Optical Coherence Tomography ( OCT ) and/or decrease visual acuity great equal 5 letter best previous visit . Only one eye enrol study .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Age 50 year . Choroidal neovascularization secondary AMD central retinal thickness great equal 300um . Best correct visual acuity study eye 20/40 20/400 use ETDRS chart Pregnancy ( positive urine pregnancy test ) lactation . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Participation study investigational drug device within past 30 day prior enrol study . Presence significant subfoveal fibrosis atrophy . Previously treat subject : Prior treatment antiVEGF therapy study eye within 28 day baseline More six ( 6 ) prior treatment antiVEGF therapy study eye within 1 year . Prior treatment PDT within past 3 month 2 prior PDT treatment . Prior treatment intravitreal aflibercept injection Prior treatment triamcinolone study eye within 6 month baseline . Prior treatment dexamethasone study eye within 30 day prior baseline . Intraocular surgery ( include cataract surgery ) study eye within 2 month precede baseline History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye . Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . Uncontrolled glaucoma study eye ( define IOP great equal 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . History allergy fluorescein , ICG iodine , amenable treatment History retinal pigment epithelial tear rip .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Choroidal neovascularization due AMD</keyword>
</DOC>